RGene Therapeutics Inc. regulatory update

The Woodlands, Texas, company received an Australian patent and notice of allowance for a U.S. Patent. Australian Patent No. 651,650 covers RGene's RGG-0853, a gene therapy product that suppresses HER-2/neu, an oncogene involved in ovarian, breast and lung cancers. RGG-0853, which initially is being developed to treat ovarian cancer, is composed of E1A, a gene from a common virus that suppresses the overexpression of HER-2/neu, and a cationic lipid vector. ...